Impact of Chronic Kidney Disease and Platelet Reactivity on Clinical Outcomes Following Percutaneous Coronary Intervention

Pietro Manuel Ferraro, Roberto Mangiacapra, Fabio Mangiacapra, Alessandro Sticchi, Edoardo Bressi, Michele Mattia Viscusi, Iginio Colaiori, Elisabetta Ricottini, Ilaria Cavallari, Silvia Spoto, Gian Paolo Ussia, Francesco Grigioni

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

We investigated the interaction between chronic kidney disease (CKD) and high platelet reactivity (HPR) in determining long-term clinical outcomes following elective PCI for stable coronary artery disease (CAD). A total of 500 patients treated with aspirin and clopidogrel were divided based on the presence of CKD (defined as glomerular filtration rate of < 60 ml/min/1.73 m2) and HPR (defined as a P2Y12 reaction unit value ≥ 240 at VerifyNow assay). Primary endpoint was the occurrence of major adverse clinical events (MACE) at 5 years. Patients with both CKD and HPR showed the highest estimates of MACE (25.6%, p = 0.005), all-cause death (17.9%, p = 0.004), and cardiac death (7.7%, p = 0.004). The combination of CKD and HPR was an independent predictor of MACE (HR 3.12, 95% CI 1.46–6.68, p = 0.003). In conclusion, the combination of CKD and HPR identifies a cohort of patients with the highest risk of MACE at 5 years.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaJournal of Cardiovascular Translational Research
DOI
Stato di pubblicazionePubblicato - 2021

Keywords

  • Chronic kidney disease
  • Platelet reactivity
  • Percutaneous coronary intervention
  • Coronary artery disease

Fingerprint

Entra nei temi di ricerca di 'Impact of Chronic Kidney Disease and Platelet Reactivity on Clinical Outcomes Following Percutaneous Coronary Intervention'. Insieme formano una fingerprint unica.

Cita questo